Acadia Pharmaceuticals announced that its drug remlifanserin will proceed to Phase 3 trials for Alzheimer's disease psychosis, despite narrowly missing the primary endpoint in Phase 2. The drug showed significant efficacy on a key secondary endpoint and a favorable safety profile, suggesting continued development is warranted and could be a positive long-term driver for the company.
Acadia Pharmaceuticals announced Phase 2 results for remlifanserin, a drug for Alzheimer's disease psychosis. While it narrowly missed the primary endpoint (p=0.0603), it showed statistical significance on a key secondary endpoint (p=0.0077) and a favorable safety profile. This outcome is a positive development for Acadia, as it allows them to continue with Phase 3 studies, removing the less effective 30mg dose. For traders, this indicates continued progress in their pipeline, reducing immediate clinical trial risk and offering long-term upside potential if Phase 3 is successful. The 'narrow miss' on the primary endpoint could lead to some initial volatility, but the overall decision to advance suggests confidence in the drug's potential.